{
    "ticker": "HTCR",
    "name": "Hoth Therapeutics, Inc.",
    "description": "Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients suffering from chronic skin conditions and other unmet medical needs. Founded in 2018 and headquartered in New York, Hoth is dedicated to advancing its proprietary drug candidates through clinical trials and regulatory approval processes. The company's lead product candidate, HT-001, is designed to treat atopic dermatitis, and it leverages a unique mechanism of action aimed at reducing inflammation and improving skin conditions. Hoth's development pipeline also includes additional formulations targeting various dermatological conditions, showcasing the company's commitment to addressing the challenges faced by patients with skin disorders. Hoth Therapeutics emphasizes collaboration with leading research institutions and industry partners to enhance its research and development capabilities. The company is poised to make significant contributions to the dermatology field, with a vision to provide effective, safe, and affordable treatment options for patients worldwide. Hoth Therapeutics aims to improve the quality of life for individuals suffering from chronic skin conditions while also delivering value to its stakeholders through strategic growth and innovation.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.hoththerapeutics.com",
    "ceo": "Robb Knie",
    "social_media": {
        "twitter": "https://twitter.com/HothTherapeutics",
        "linkedin": "https://www.linkedin.com/company/hoth-therapeutics-inc"
    },
    "investor_relations": "https://www.hoththerapeutics.com/investors",
    "key_executives": [
        {
            "name": "Robb Knie",
            "position": "CEO"
        },
        {
            "name": "Dr. John DeForest",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "HT-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Hoth Therapeutics, Inc. | Innovative Dermatological Solutions",
        "meta_description": "Explore Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for chronic skin conditions.",
        "keywords": [
            "Hoth Therapeutics",
            "Biotechnology",
            "Pharmaceuticals",
            "Dermatology",
            "Atopic Dermatitis"
        ]
    },
    "faq": [
        {
            "question": "What does Hoth Therapeutics focus on?",
            "answer": "Hoth Therapeutics focuses on developing innovative therapeutics for chronic skin conditions and unmet medical needs."
        },
        {
            "question": "Who is the CEO of Hoth Therapeutics?",
            "answer": "Robb Knie is the CEO of Hoth Therapeutics, Inc."
        },
        {
            "question": "Where is Hoth Therapeutics headquartered?",
            "answer": "Hoth Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Hoth's lead product candidate?",
            "answer": "Hoth's lead product candidate is HT-001, aimed at treating atopic dermatitis."
        },
        {
            "question": "When was Hoth Therapeutics founded?",
            "answer": "Hoth Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "VRTX",
        "REGN",
        "MRNA",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "ABBV",
        "GILD"
    ]
}